一种创新的免疫治疗疫苗联合检查点阻断作为胶质母细胞瘤当前治疗背景下的一线治疗方法。
An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments.
作者信息
Coxon Andrew T, Johanns Tanner M, Dunn Gavin P
机构信息
Andrew T. Coxon, MS2, Department of Neurological Surgery; Tanner M. Johanns, MD, PhD, Assistant Professor of Medicine, Division of Medical Oncology; and Gavin P. Dunn, MD, PhD, (above), Associate Professor of Neurological Surgery, Director of Brain Tumor Immunology and Therapeutics, and the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs; all are at Washington University School of Medicine, St. Louis, Missouri.
出版信息
Mo Med. 2020 Jan-Feb;117(1):45-49.
Glioblastoma is a devastating disease with a dismal prognosis. While recent advancements in cancer immunotherapy have led to improvements in treating other types of cancer, patients with glioblastoma have not benefited from these new therapies and techniques. Fortunately, neurosurgeons and oncologists at Washington University School of Medicine conducting a cutting edge clinical trial are looking to overcome these persistent challenges in treating glioblastoma through combining a personalized vaccine with new immunotherapy drugs.
胶质母细胞瘤是一种预后极差的毁灭性疾病。尽管癌症免疫疗法最近取得的进展已使其他类型癌症的治疗有所改善，但胶质母细胞瘤患者尚未从这些新疗法和技术中获益。幸运的是，华盛顿大学医学院的神经外科医生和肿瘤学家正在进行一项前沿临床试验，希望通过将个性化疫苗与新的免疫疗法药物相结合，来克服胶质母细胞瘤治疗中这些长期存在的挑战。
Zotero 插件